ZD6126 directly affects the internal structure of the endothelial cell, whereas gefitinib acts through inhibition of EGFR signalling of endothelial cells and by reduced production of proangiogenic factors by tumour cells (Hirata et al, 2002). This evidence concerns the gene EGFR and neoplasm.